FULGENT ALERT: Bragar Eagel & Squire, P.C. is Investigating Fulgent Genetics, Inc. on Behalf of Fulgent Stockholders and Encourages Investors to Contact the Firm

Core Viewpoint - Fulgent Genetics, Inc. is under investigation for potential violations of federal securities laws and unlawful business practices, following a civil investigative demand from the U.S. Department of Justice regarding false claims submitted under the Uninsured Program [1][2]. Group 1: Company Investigation - Bragar Eagel & Squire, P.C. is investigating potential claims against Fulgent on behalf of its stockholders [1]. - The investigation is focused on whether Fulgent has engaged in unlawful business practices or violated federal securities laws [1]. - Following the disclosure of the civil investigative demand, Fulgent's stock price decreased by $0.41 per share, or 2.61$15.28 per share [2]. Group 2: Legal Context - The civil investigative demand was received by Fulgent from the U.S. Department of Justice, indicating serious scrutiny regarding the company's claims under the Uninsured Program [2]. - The law firm Bragar Eagel & Squire, P.C. specializes in representing investors in complex litigation, which includes securities and derivative cases [4].